title: The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
authors.affiliation: Internal Medicine 3, Department of Medicine, University of Padua, via Giustiniani 2, 35128, Padova, Italy. roberto.vettor@unipd.it.
authors.forename: Roberto
authors.initials: R
authors.lastname: Vettor
authors.affiliation: Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
authors.forename: Silvio E
authors.initials: SE
authors.lastname: Inzucchi
authors.affiliation: Internal Medicine 3, Department of Medicine, University of Padua, via Giustiniani 2, 35128, Padova, Italy. paola.fioretto@unipd.it.
authors.forename: Paola
authors.initials: P
authors.lastname: Fioretto
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000378:metabolism / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control; D058065:Diabetic Cardiomyopathies / Q000517:prevention & control; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D049990:Membrane Transport Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D008954:Models, Biological; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D049990:Membrane Transport Modulators; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C570240:empagliflozin
keywords: Cardiovascular disease; Empagliflozin; Heart failure; Mitochondrial function; NHE; SGLT2 inhibitors; Type 2 diabetes